{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/rosacea/background-information/prevalence/","result":{"pageContext":{"chapter":{"id":"df406671-3834-580f-836a-3c2428245359","slug":"prevalence","fullItemName":"Prevalence","depth":2,"htmlHeader":"<!-- begin field f2d796bb-88d4-498c-a92a-cc411fc53250 --><h2>How common is it?</h2><!-- end field f2d796bb-88d4-498c-a92a-cc411fc53250 -->","summary":"","htmlStringContent":"<!-- begin item faa3123c-476d-43d8-8de3-21a4967f0143 --><!-- begin field 8de20bf1-e957-400c-8d80-428878e28d46 --><p><strong>The prevalence of rosacea varies depending on the populations studied, diagnostic tools used, and study methodological approach </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Gether, 2018</a>]<strong>.</strong></p><ul><li>A global systematic review of 32 population-based and secondary care studies (n = 26,519,836 adults) found [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Gether, 2018</a>]:<ul><li>The pooled prevalence of rosacea in the general population was 5.46%, and 2.39% in dermatology outpatients.</li><li>Women were affected more commonly than men (prevalence rates of 5.41% and 3.9%, respectively).</li><li>Rosacea mainly affected people aged 45–60 years.</li></ul></li><li>A multi-centre, interventional, cross-sectional study in Germany (n = 3052) and Russia (n = 3013) found a prevalence of rosacea of 12.3% and 5%, respectively, diagnosed by initial questionnaire and then confirmed on clinical examination. The demographic profile of people affected was similar between the two countries [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Tan, 2016</a>]:<ul><li>75% of people affected were women, and the mean age was 40 years.</li><li>People with fair skin were predominantly affected (skin phototype II and III).</li><li>The authors reported that the prevalence in Germany may have been an underestimate, owing to the study design.</li></ul></li><li>A Swedish non-selected study (n = 809) found a prevalence of rosacea of 10% (women 14%, men 5%) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Berg, 1989</a>].</li><li>Expert opinion in a review article notes that rosacea usually develops in people between 30–50 years of age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2017</a>].</li><li>Rosacea is most frequently observed in people with fair skin types [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Gallo, 2018</a>].<ul><li>It may be under-reported and under-diagnosed in people with pigmented skin, owing to the difficulty in identifying erythema and telangiectasia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Tan, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Alexis, 2019</a>].</li></ul></li><li>Expert opinion in a review article notes that women are affected more often than men, but men are more likely to have more severe presentations, such as phymatous changes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Oge, 2015</a>].</li><li>Ocular rosacea is estimated to occur in up to three-quarters of people with skin involvement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2017</a>].</li></ul><!-- end field 8de20bf1-e957-400c-8d80-428878e28d46 --><!-- end item faa3123c-476d-43d8-8de3-21a4967f0143 -->","topic":{"id":"907deb55-501c-50b0-9c07-5956c70cf201","topicId":"d6855039-5025-454d-b195-d4b0a3763978","topicName":"Rosacea ","slug":"rosacea","lastRevised":"Last revised in January 2021","chapters":[{"id":"a3d8bb8f-cf98-5320-abe8-71c7b0c3d604","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a9c3b514-8e94-52d5-8de7-2caedcdd8ed3","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"efe24f29-88ad-5507-b4b5-ec00c54a404d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"10634254-4474-5303-9337-e3682fd14514","slug":"changes","fullItemName":"Changes"},{"id":"1ad5ada5-1ed7-5223-b60c-122b20127e1e","slug":"update","fullItemName":"Update"}]},{"id":"832a95da-0571-5031-b437-3cc5568bc7fa","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"59d41997-63c3-57d4-8c29-c4655d090e7a","slug":"goals","fullItemName":"Goals"},{"id":"2c3bc0a5-be4b-5a98-a5d8-02e7cb85b9cb","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f8c34a65-7879-5a21-87df-68739ba5d1f3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9f050a9b-10be-5d79-b662-0099ac611890","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9fcdbb11-1f96-5ae9-aeec-617a9da55e12","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"538579d3-7620-5145-a70f-022ec13226ae","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d0b606da-7836-5c33-8390-23a6dad9e7bd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ed198aaf-1444-5590-ab74-c9fdff996b5e","slug":"definition","fullItemName":"Definition"},{"id":"df406671-3834-580f-836a-3c2428245359","slug":"prevalence","fullItemName":"Prevalence"},{"id":"be28c459-5653-506e-937c-5c4d2f7ceecd","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"bc98e144-7d7d-5fa2-97ad-7c1bd8526ca0","slug":"complications","fullItemName":"Complications"},{"id":"1a5cbcf6-2870-5a82-a207-8c8888f907d2","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"d654b61f-b47e-5123-b965-f806f0eb2e6d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"bd6d5455-d63e-5507-8bdd-028b338047cc","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"30d3265f-84ec-5ac7-a410-bc11cd078ac9","slug":"assessment","fullItemName":"Assessment"},{"id":"e111154d-c82a-5292-b201-f4a12a8a4d17","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"e753e991-54fe-5ab5-96d2-124372f1292f","fullItemName":"Management","slug":"management","subChapters":[{"id":"0e7b3ebf-33f5-5b51-a9ab-81c8dda1332f","slug":"rosacea","fullItemName":"Scenario: Rosacea"}]},{"id":"602c95a0-f64e-593e-85c4-798ea728733b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e6e7bc13-b6bd-5b5e-b337-196c3291ee63","slug":"topical-treatments","fullItemName":"Topical treatments"},{"id":"c53198f5-f60b-5fb6-8767-9f9a275329f5","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"}]},{"id":"0db34d3f-c02f-5b8f-8498-90541139bc2a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ca47aba9-e0da-5e0a-a1a2-46bfab6fe609","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5c0a0103-4ed2-586f-8fbd-aaf6fe82f548","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"84966474-462f-592c-b43d-474d1ca89d52","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bb2d8252-c981-52ba-9faf-d9e9450efe7c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f5e586ed-912a-51ab-b246-3a6f6c67e2d1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a60f4af9-1a6a-5a71-9310-2b3fe7d0cb92","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"40a50d91-c85e-5b2c-b283-ca2a9f30c6f0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d0b606da-7836-5c33-8390-23a6dad9e7bd","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}